The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-31. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
== Research == Brodbelt's research centers on the development of mass spectrometry-based methods to characterize organic molecules. Brodbelt's early research established methods to use chemical ionization in ion trap mass spectrometers and applied this method to the analysis of petroleum samples. She subsequently worked on gas-phase ion chemistry and photodissociation as methods to break apart organic compounds before they are analyzed by a mass spectrometer. Her work has led to the analysis of compounds including recreational drugs, sunscreen, and pesticides. Her work also includes investigations into proteins and other organic compounds produced by bacteria, such as lipopolysaccharides. In her research, she aimed to develop creative techniques for stimulating ions to produce enlightening fragmentation patterns.
Integrative, multi-locus studies have prompted major revisions of several lichen families and genera. Two examples illustrate the impact of these studies: the re-circumscription of the family Graphidaceae and of the family Ramalinaceae. Graphidaceae—the script lichen family—contains more than 2,000 mostly tropical species. Traditional taxonomy centred on fruiting body shape and a few microscopic characters. A five-locus phylogeny (Rivas-Plata and Lumbsch 2011) showed that many characters had evolved convergently. Slit-like versus rounded discs arose repeatedly, so genera built on those traits mixed unrelated species. Molecular results led to a wholesale recircumscription: several traditional genera were divided and new ones erected to reflect monophyletic clades. For instance, the broad Graphis was split into several smaller, genetically and chemically homogeneous genera. This process was facilitated by projects such as Ticolichen (a tropical lichen inventory project) which combined fieldwork, morphology, chemistry, and DNA sequencing to tackle these revisions. The outcome is a more natural scheme: genera now align with monophyletic clades, even when outwardly dissimilar species must be grouped together. The revision greatly increased recognized genera and species, exposing hidden diversity in tropical crustose lichens. Another major revision, in this case of a mostly temperate/tropical group, was carried out by Kistenich and colleagues (2018) on the family Ramalinaceae. The family had about 40 genera of uncertain affinity, several delimited by only one or two traits.
Ansuvimab was developed by the Vaccine Research Center with support of the United States National Institutes of Health and the Defense Advanced Projects Agency. The heavy and light chain sequences of ansuvimab mAb were cloned into CHO cell lines to enable large-scale production of antibody product for use in humans. In early 2018, a Phase 1 clinical trial of ansuvimab's safety, tolerability and pharmacokinetics was conducted by Dr. Martin Gaudinski within the Vaccine Research Center Clinical Trials Program that is led by Dr. Julie E. Ledgerwood. The study was performed in the United States at the NIH Clinical Center and tested single dose infusions of ansuvimab infused over 30 minutes. The study showed that ansuvimab was safe, had minimal side effects and had a half-life of 24 days. A license for ansuvimab was obtained by Ridgeback Biotherapeutics in 2018, from the National Institutes of Health-National Institute of Allergy and Infectious Diseases. Ansuvimab was given orphan drug status in May 2019 and March 2020.
Sources: en.wikipedia.org
=== C-terminal retention signals === While the N-terminus of a protein often contains targeting signals, the C-terminus can contain retention signals for protein sorting. The most common ER retention signal is the amino acid sequence -KDEL (Lys-Asp-Glu-Leu) or -HDEL (His-Asp-Glu-Leu) at the C-terminus. This keeps the protein in the endoplasmic reticulum and prevents it from entering the secretory pathway.
Mass spectrometry is one of the key methods to study the proteome. Some important mass spectrometry methods include Orbitrap Mass Spectrometry, MALDI (Matrix Assisted Laser Desorption/Ionization), and ESI (Electrospray Ionization). Peptide mass fingerprinting identifies a protein by cleaving it into short peptides and then deduces the protein's identity by matching the observed peptide masses against a sequence database. Tandem mass spectrometry, on the other hand, can get sequence information from individual peptides by isolating them, colliding them with a non-reactive gas, and then cataloguing the fragment ions produced. In May 2014, a draft map of the human proteome was published in Nature. This map was generated using high-resolution Fourier-transform mass spectrometry. This study profiled 30 histologically normal human samples resulting in the identification of proteins coded by 17,294 genes. This accounts for around 84% of the total annotated protein-coding genes.
In 2011, Whirlpool celebrated its 100th anniversary and unveiled its 100th anniversary logo and an updated corporate logo. It also took over the former KarstadtQuelle brand Privileg from Otto GmbH. In 2011, Whirlpool announced the closure of the Fort Smith Arkansas plant. The following year Whirlpool opened a manufacturing plant in Cleveland, Tennessee replacing a 123-year-old facility. The $200 million project added about 130 jobs to an established workforce of 1,500. The 1-million-square-foot (93,000 m2) facility manufactures premium cooking appliances for Whirlpool's portfolio of brands. The project includes a distribution center. In August 2013, Whirlpool announced it would acquire a 51% majority stake in China's Hefei Royalstar Sanyo (a joint venture between Japan's Sanyo Electric Co, now a unit of Panasonic Corp, and Hefei State-Owned Assets Holding Company Ltd, the investment arm of the local state government) for $552 million and give the company leverage to expand in the Chinese appliance market. In July 2014, Whirlpool announced it would pay €758 million ($1 billion) to buy a 60% stake in the Italian rival Indesit. In December Whirlpool completed a successful mandatory tender offer for the remaining shares and de-listed Indesit from the Milan Stock Exchange, becoming a wholly owned subsidiary of Whirlpool Italia Holdings S.r.l. On May 18, 2015, Whirlpool announced that it will acquire American Dryer Corporation, a manufacturer of dryers based in Fall River, Massachusetts. The acquisition was completed on July 3rd of the year.
A conserved N-terminal domain containing a cysteine rich region (12 cysteine residues) with multiple intra-domain disulfide bonds, an IGFBP motif (GCGCCXXC), the primary site of IGF binding. A highly variable central or linker domain (only 15% conservation between IGFBPs). A conserved C-terminal domain containing secondary IGF binding residues, a cysteine rich region (6 cysteine residues), an 18 residue basic motif that binds heparin, the acid labile subunit (ALS), and a nuclear localization sequence. The linker domain is the site of most post-translational modification, which include glycosylation, phosphorylation, and limited proteolysis. By electrophoretic analysis IGFBP-3 appears as a doublet, owing to the occupancy of either two or three of its N-glycosylation sites by carbohydrate. Hypoglycosylated IGFBP-3 may be seen after extended glucose starvation. Many proteases are known to cleave IGFBP-3 at single linker-domain sites, and in the circulation of pregnant women, IGFBP-3 is entirely proteolyzed, yet still capable of carrying normal amounts of IGF-1 and IGF-2. Binding capacity appears to be retained after proteolysis because of a cooperative interaction between the two proteolyzed fragments, that together maintain an active IGF-binding site.
Sources: en.wikipedia.org
== Original restaurant == The first In-N-Out restaurant that opened in 1948 was demolished when Interstate 10 (then US 60/US 70/US 99, the Ramona Freeway, now the San Bernardino Freeway) was built from downtown Los Angeles to the San Gabriel Valley. The freeway runs over the original location. A new restaurant was completed in 1954 near the original Baldwin Park, California, location. It was closed in November 2004 and demolished on April 16, 2011, despite discussions about using it as an In-N-Out museum chronicling the origins and history of the company. In-N-Out built a replacement restaurant on the other side of the freeway next to the original In-N-Out University (opened in 1984). A new In-N-Out University was built on the property. The university building houses the training department, which was moved from Irvine, California. In addition, the company restaurant was moved from In-N-Out's Baldwin Park headquarters to the new lot, which holds the restaurant and university, less than a thousand feet away. In 2014, a replica of the first In-N-Out was built in Baldwin Park.
The expanding liver bud is colonized by hematopoietic cells. The bipotential hepatoblasts begin differentiating into biliary epithelial cells and hepatocytes. The biliary epithelial cells differentiate from hepatoblasts around portal veins, first producing a monolayer, and then a bilayer of cuboidal cells. In ductal plate, focal dilations emerge at points in the bilayer, become surrounded by portal mesenchyme, and undergo tubulogenesis into intrahepatic bile ducts. Hepatoblasts not adjacent to portal veins instead differentiate into hepatocytes and arrange into cords lined by sinusoidal epithelial cells and bile canaliculi. Once hepatoblasts are specified into hepatocytes and undergo further expansion, they begin acquiring the functions of a mature hepatocyte, and eventually mature hepatocytes appear as highly polarized epithelial cells with abundant glycogen accumulation. In the adult liver, hepatocytes are not equivalent, with position along the portocentrovenular axis within a liver lobule dictating expression of metabolic genes involved in drug metabolism, carbohydrate metabolism, ammonia detoxification, and bile production and secretion. WNT/β-catenin has been identified as playing a key role in this phenomenon.
phase diagram A graphical representation of the equilibrium relationships between thermodynamically distinct phases of a chemical compound, mixture, or solution, indicating the physical conditions (e.g. temperature and pressure) under which various phases (e.g. solid, liquid, and vapor) occur or coexist.
The First Amendment guarantees the free exercise of religion in the country and forbids Congress from passing laws respecting its establishment. Religious practice is widespread, among the most diverse in the world, and profoundly vibrant. The country has the world's largest Christian population, which includes the fourth-largest population of Catholics. Other notable faiths include Judaism, Buddhism, Hinduism, Islam, New Age, and Native American religions. Religious practice varies significantly by region. "Ceremonial deism" is common in American culture. The overwhelming majority of Americans believe in a higher power or spiritual force, engage in spiritual practices such as prayer, and consider themselves religious or spiritual. In the Southern United States' "Bible Belt", evangelical Protestantism plays a significant role culturally; New England and the Western United States tend to be more secular. Mormonism, a Restorationist movement founded in the U.S. in 1830, is the predominant religion in Utah and a major religion in Idaho.
=== Potential benefits === Increased health awareness: Regular testing can help individuals identify health trends and potential issues early, enabling proactive health management. Convenience and accessibility: At-home collection and direct ordering eliminate barriers such as scheduling appointments, obtaining referrals, and taking time off work. Cost transparency: Upfront pricing allows consumers to make informed decisions about testing costs. Patient empowerment: Direct access to health data supports informed decision-making and engagement in personal health management. In 2014 the federal government issued a regulation directing clinical laboratories to provide individuals with access to their test data upon request.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.